Glutamatergic Adaptation to Stress as a Mechanism for Anhedonia and Treatment Response With Ketamine
Study Details
Design, interventions, and primary outcomes
About This Study
The main purpose of this study is to investigate the effects of ketamine on decision-making and emotion processing in a sample of individuals diagnosed with Major Depressive Disorder (MDD).
Design
Interventions / Regimen
- Drug: Ketamine — A single intravenous (IV) infusion of ketamine calculated at 0.5mg/kg through an indwelling catheter over a 40-100min period.
- Other: Placebo — A single intravenous (IV) infusion of saline through an indwelling catheter over a 40-100min period.
Primary Outcomes
- Change in glutamate concentration in the medial prefrontal cortex (mPFC) (Baseline, 24 hours post-infusion, 14 days post-infusion)
Phase: EARLY_PHASE1
Status: Recruiting
Start Date: 2022-11-08
Completion: 2028-03-02
Sex: ALL
Volunteers: true
Enrollment: 140 (ESTIMATED)
Collaborators: National Institute of Mental Health (NIMH)
- Michael Treadway, PhD (PRINCIPAL_INVESTIGATOR) - Emory University
- Drug: Ketamine — A single intravenous (IV) infusion of ketamine calculated at 0.5mg/kg through an indwelling catheter over a 40-100min period.
- Other: Placebo — A single intravenous (IV) infusion of saline through an indwelling catheter over a 40-100min period.